Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna

Selma Tobudic; Christina Forstner; Heinz Burgmann; Heimo Lagler; Michael Ramharter; Christoph Steininger; Matthias G Vossen; Stefan Winkler; Florian Thalhammer

doi:10.1093/cid/ciy279

Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna

Selma Tobudic
Christina Forstner
Heinz Burgmann
Heimo Lagler
Michael Ramharter
Christoph Steininger
Matthias G Vossen
Stefan Winkler
Florian Thalhammer

Beteiligte Einrichtungen

I. Medizinische Klinik und Poliklinik

Abstract

The clinical outcomes and safety of dalbavancin as primary and sequential treatment of gram-positive bacteremia with infective endocarditis were evaluated retrospectively. The clinical success rate was high (92.6%), but in 24 of 27 patients dalbavancin was used only after clearance of bacteria from the bloodstream.

Bibliografische Daten

Originalsprache	Englisch
ISSN	1058-4838
DOIs	https://doi.org/10.1093/cid/ciy279
Status	Veröffentlicht - 16.08.2018

PubMed	29659732